BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Reig M, Díaz-González Á, Bruix J. The success of regorafenib in hepatocellular carcinoma in a world of failures. Learnings for future developments. Oncotarget 2017;8:106151-2. [PMID: 29290927 DOI: 10.18632/oncotarget.22382] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
Number Citing Articles
1 Cerrito L, Ponziani FR, Garcovich M, Tortora A, Annicchiarico BE, Pompili M, Siciliano M, Gasbarrini A. Regorafenib: a promising treatment for hepatocellular carcinoma. Expert Opin Pharmacother. 2018;19:1941-1948. [PMID: 30345837 DOI: 10.1080/14656566.2018.1534956] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
2 Brown ZJ, Hewitt DB, Pawlik TM. Experimental drug treatments for hepatocellular carcinoma: Clinical trial failures 2015 to 2021. Expert Opin Investig Drugs 2022. [PMID: 35580650 DOI: 10.1080/13543784.2022.2079491] [Reference Citation Analysis]
3 Reig M, da Fonseca LG, Faivre S. New trials and results in systemic treatment of HCC. J Hepatol 2018;69:525-33. [PMID: 29653122 DOI: 10.1016/j.jhep.2018.03.028] [Cited by in Crossref: 29] [Cited by in F6Publishing: 34] [Article Influence: 7.3] [Reference Citation Analysis]
4 Díaz-gonzález Á, Sanduzzi-zamparelli M, Sapena V, Torres F, Llarch N, Iserte G, Forner A, da Fonseca L, Ríos J, Bruix J, Reig M. Systematic review with meta-analysis: the critical role of dermatological events in patients with hepatocellular carcinoma treated with sorafenib. Aliment Pharmacol Ther 2019;49:482-91. [DOI: 10.1111/apt.15088] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 9.3] [Reference Citation Analysis]
5 Siepmann J, Faham A, Clas SD, Boyd BJ, Jannin V, Bernkop-Schnürch A, Zhao H, Lecommandoux S, Evans JC, Allen C, Merkel OM, Costabile G, Alexander MR, Wildman RD, Roberts CJ, Leroux JC. Lipids and polymers in pharmaceutical technology: Lifelong companions. Int J Pharm 2019;558:128-42. [PMID: 30639218 DOI: 10.1016/j.ijpharm.2018.12.080] [Cited by in Crossref: 49] [Cited by in F6Publishing: 42] [Article Influence: 16.3] [Reference Citation Analysis]